Co-crystals: A Novel Approach to Improve the Solubility of Apixaban

被引：1
|
作者：
Asati, Amit, V [1 ,6 ]
Salunkhe, Kishor S. [2 ]
Rajput, Rudra Pratap Singh [3 ]
Chintamani, Sonali R. [4 ]
Khairnar, Akshay U. [5 ]
Patil, Nilesh S. [5 ]
Chintamani, Ravindra N. [5 ]
机构：
[1] Amrutvahini Coll Pharm, Dept Pharmaceut, Ahmednagar, Maharashtra, India
[2] Sanjivani Coll Pharmaceut Educ & Res, Dept Pharmaceut, Kopargaon, Maharashtra, India
[3] Columbia Inst Pharm, Dept Pharmaceut, Raipur, Chhattisgarh, India
[4] MCE Soc Allana Coll Pharm, Dept Pharmaceut, Pune, Maharashtra, India
[5] Inst Pharm, Rajmata Jijau Shikshan Prasarak Mandals, Dept Pharmaceut, Pune, Maharashtra, India
[6] Amrutvahini Coll Pharm, Sangamner 422608, Maharashtra, India
来源：
INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION | 2023年 / 13卷 / 02期
关键词：
Apixaban; Co-crystal; Solubility; Oxalic acid; DRUG;
D O I：
10.5530/ijpi.13.2.033
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Objectives:The current study work was aimed to improve the solubility of Apixaban by forming co-crystals. Materials and Methods: Two solvents mainly Dimethyl Sulphoxide (DMSO) and 2,2,2-trifluoroethanol were tried during the formulation of co-crystals. The other chemicals oxalic acid, adipic acid and L-Tartaric acid were used. Results: From the different trials it was concluded that oxalic acid and DMSO combination with the drug gave the better results for improvement in the solubility. Hence the batch F3 was analysed further. The melting point of F3 was found lower than pure drug. Drug content was found optimum as 95.06 +/- 0.65%. FTIR-spectra demonstrated the combined peaks of drug and oxalic acid. DSC thermogram showed the sharp endothermic peak similar to pure drug. SEM and XRD spectra confirmed the formation of co-crystals. Conclusion: It was found that formation of co-crystals of apixaban and oxalic acid was satisfactory and it was beneficial to improve the solubility of the apixaban.
引用
收藏
页码：243 / 247
页数：5
相关论文
共 50 条
  • [41] Pharmaceutical co-crystals: A green way to enhance drug stability and solubility for improved therapeutic efficacy
    Chettri, Anisha
    Subba, Ankita
    Singh, Govind P.
    Bag, Partha Pratim
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2024, 76 (01) : 1 - 12
  • [42] Drug-Polymer Co-Crystals of Dapsone and Polyethylene Glycol: An Emerging Subset in Pharmaceutical Co-Crystals
    Chappa, Praveen
    Maruthapillai, Arthanareeswari
    Voguri, Rajasekhar
    Dey, Archan
    Ghosal, Subhas
    Basha, Mohamed Amjad
    CRYSTAL GROWTH & DESIGN, 2018, 18 (12) : 7590 - 7598
  • [43] STRUCTURE OF CO-CRYSTALS OF TROPOMYOSIN AND TROPONIN
    WHITE, SP
    COHEN, C
    PHILLIPS, GN
    NATURE, 1987, 325 (6107) : 826 - 828
  • [44] Manufacture and biopharmaceutical properties of co-crystals
    Eigbire, M.
    Forbes, B.
    Towler, C.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2008, 60 : A34 - A35
  • [45] Co-crystals, polymorphs and their photochemistry.
    Khoj, M.
    Kariuki, B.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2013, 69 : S634 - S634
  • [46] Co-crystals of fenamic acids with ethacridine
    Krawczyk, Marta
    Glod, Sara
    Majerz, Irena
    Krawczyk, Monika K.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : E192 - E192
  • [47] NMR crystallography of ezetimibe co-crystals
    Luedeker, David
    Brunklaus, Gunther
    SOLID STATE NUCLEAR MAGNETIC RESONANCE, 2015, 65 : 29 - 40
  • [48] The role of co-crystals in pharmaceutical design
    Steed, Jonathan W.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2013, 34 (03) : 185 - 193
  • [49] Pharmaceutical co-crystals - are we there yet?
    Blagden, N.
    Colesb, S. J.
    Berry, D. J.
    CRYSTENGCOMM, 2014, 16 (26): : 5753 - 5761
  • [50] Preparation and characterization of carprofen co-crystals
    Bruni, Giovanna
    Maietta, Mariarosa
    Berbenni, Vittorio
    Bini, Marcella
    Ferrari, Stefania
    Capsoni, Doretta
    Boiocchi, Massimo
    Milanese, Chiara
    Marini, Amedeo
    CRYSTENGCOMM, 2012, 14 (02): : 435 - 445
12345